Purpose: To address iron deficiency in adolescent female cross country runners, a twelve week prospective clinical trial was conducted to analyze the efficacy of daily versus weekly iron therapy. Design: 47 female cross country runners [ages 14-18 years] were screened for iron deficiency [ferritin <20mg/dl] before the season. The participants were randomized to the daily treatment group[648mg FeSO4 qd (910mg elemental iron/wk)] or the weekly group [648mg FeSO4q week (130 mg elemental iron/wk)]. Intention to treat analysis, with paired t test and Mann Whitney U for nonparametric test for treatment group differences, was used. Results: The two groups had similar baseline parameters including demographics, aerobic fitness, hematologic indices [hemoglobin, hematocrit, ferritin, MCV, transferrin saturation] and iron absorption [analysis uses thermal ionization mass spectrometry of multiple-trace stable isotope using 58Fe administered prior to therapy and 57Fe after 6 weeks of therapy]. Of 17 runners who qualified for the study, 10 runners [4 daily, 6 weekly] completed the study protocol [2 refused to participate after the screening process, 5 (4 daily, 1 weekly, p=.15) were excluded because of noncompliance (less than 50% of prescribed medication)]. Side effects from the medication were related to noncompliance (p=.03). Those who were compliant in the daily group had a greater increase in their ferritin concentration [daily 19.0±8.2, weekly 3.5±5.0, p=.01] and final ferritin level [daily 34.2±6.5, weekly 15.0±9.9, p=.01]. Intention to treat analysis demonstrated no difference between treatment groups in hematologic indices and aerobic fitness. Over the study period, iron absorption in the daily group decreased by 71% [initially 20.5±4.9 to 6.0±5.9], while the weekly group decreased by 49% [initially 29.6±18.5 to 15.1±6.4], not significantly different (p=.20). The total amount of elemental iron incorporated per week for the daily group was 2.7 times the weekly group[daily 49.5±48.8mg, weekly 17.7±7.5mg, p=.67] and only 2.5 times the weekly dose when reported compliance was used [daily 38.7±mg, weekly 15.3±mg, p=.83]. Conclusions: Noncompliance and decreased iron absorption limit the effectiveness of daily iron therapy. One hypothesis is that higher weekly or twice weekly dosing may optimize absorption compliance.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chorley, J., Abrams, S., Vehrs, P. et al. Daily Versus Weekly Supplementation for Iron Deficiency in Female Adolescent Cross Country Runners 2. Pediatr Res 43 (Suppl 4), 3 (1998). https://doi.org/10.1203/00006450-199804001-00023
Issue Date:
DOI: https://doi.org/10.1203/00006450-199804001-00023